



## Clinical trial results:

### A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

#### Summary

|                          |  |
|--------------------------|--|
| EudraCT number           | 2016-003123-32   |
| Trial protocol           | SK CZ DE GB PT IE BG AT LV PL BE NL EE SE ES GR NO LT HR |
| Global end of trial date | 14 April 2021  |

#### Results information

|                                |                 |
|--------------------------------|-----------------|
| Result version number          | v1 (current)    |
| This version publication date  | 14 October 2021 |
| First version publication date | 14 October 2021 |

#### Trial information

##### Trial identification

|                       |         |
|-----------------------|---------|
| Sponsor protocol code | M16-006 |
|-----------------------|---------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT03105128 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |   |
|------------------------------|---|
| Sponsor organisation name    | AbbVie Deutschland GmbH & Co. KG  |
| Sponsor organisation address | AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, United Kingdom, SL6 4UB                                     |
| Public contact               | Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a> |
| Scientific contact           | Global Medical Services, AbbVie, 001 8006339110, <a href="mailto:abbvieclinicaltrials@abbvie.com">abbvieclinicaltrials@abbvie.com</a> |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |               |
|--|---------------|
| Analysis stage                                       | Final         |
| Date of interim/final analysis                       | 14 April 2021 |
| Is this the analysis of the primary completion data? | No            |

|                                  |               |
|----------------------------------|---------------|
| Global end of trial reached?     | Yes           |
| Global end of trial date         | 14 April 2021 |
| Was the trial ended prematurely? | No            |

Notes:

## General information about the trial

Main objective of the trial:

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).

Protection of trial subjects:

Subject and/or legal guardian read and understood the information provided about the study and gave written permission.

Background therapy: -

Evidence for comparator: -

|   |             |
|---|-------------|
| Actual start date of recruitment                          | 10 May 2017 |
| Long term follow-up planned                               | No          |
| Independent data monitoring committee (IDMC) involvement? | Yes         |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |  |
|--------------------------------------|--|
| Country: Number of subjects enrolled | Australia: 4                               |
| Country: Number of subjects enrolled | Austria: 7                                 |
| Country: Number of subjects enrolled | Belarus: 1                                 |
| Country: Number of subjects enrolled | Belgium: 68                                |
| Country: Number of subjects enrolled | Bosnia and Herzegovina: 2                  |
| Country: Number of subjects enrolled | Brazil: 14                                 |
| Country: Number of subjects enrolled | Bulgaria: 4                                |
| Country: Number of subjects enrolled | Canada: 65                                 |
| Country: Number of subjects enrolled | Chile: 2                                   |
| Country: Number of subjects enrolled | China: 75                                  |
| Country: Number of subjects enrolled | Croatia: 14                                |
| Country: Number of subjects enrolled | Czechia: 18                                |
| Country: Number of subjects enrolled | Estonia: 3                                 |
| Country: Number of subjects enrolled | Germany: 74                                |
| Country: Number of subjects enrolled | Greece: 12                                 |
| Country: Number of subjects enrolled | Israel: 22                                 |
| Country: Number of subjects enrolled | Italy: 38                                  |
| Country: Number of subjects enrolled | Japan: 75                                  |
| Country: Number of subjects enrolled | Korea, Democratic People's Republic of: 18 |
| Country: Number of subjects enrolled | Latvia: 2                                  |
| Country: Number of subjects enrolled | Malaysia: 1                                |

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Mexico: 2              |
| Country: Number of subjects enrolled | Netherlands: 8         |
| Country: Number of subjects enrolled | New Zealand: 6         |
| Country: Number of subjects enrolled | Norway: 10             |
| Country: Number of subjects enrolled | Poland: 63             |
| Country: Number of subjects enrolled | Portugal: 14           |
| Country: Number of subjects enrolled | Romania: 6             |
| Country: Number of subjects enrolled | Russian Federation: 25 |
| Country: Number of subjects enrolled | Serbia: 23             |
| Country: Number of subjects enrolled | Singapore: 1           |
| Country: Number of subjects enrolled | Slovakia: 8            |
| Country: Number of subjects enrolled | South Africa: 27       |
| Country: Number of subjects enrolled | Spain: 18              |
| Country: Number of subjects enrolled | Sweden: 10             |
| Country: Number of subjects enrolled | Switzerland: 4         |
| Country: Number of subjects enrolled | Ukraine: 17            |
| Country: Number of subjects enrolled | United Kingdom: 25     |
| Country: Number of subjects enrolled | United States: 145     |
| Worldwide total number of subjects   | 931                    |
| EEA total number of subjects         | 377                    |

Notes:

### Subjects enrolled per age group

|   |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 9   |
| Adults (18-64 years)                      | 880 |
| From 65 to 84 years                       | 42  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details:

Subjects were randomized to receive 600mg risankizumab, 1200mg risankizumab or placebo during the double-blind, placebo-controlled Period 1. At Week 12, subjects who do not achieve clinical response were randomized into Period 2 to receive 180mg risankizumab, 360mg risankizumab or 1200mg risankizumab. Subjects who received placebo received 1200mg.

### Pre-assignment

Screening details:

A total of 931 subjects were enrolled and included in the intent-to-treat (ITT) population; 850 of those had a baseline eligible Simple Endoscopic Score for Crohn's disease (SES-CD) of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component and were included in the ITT1A population.

### Period 1

|                              |                              |
|------------------------------|------------------------------|
| Period 1 title               | Induction Period 1           |
| Is this the baseline period? | Yes                          |
| Allocation method            | Randomised - controlled      |
| Blinding used                | Double blind                 |
| Roles blinded                | Subject, Investigator, Carer |

Blinding implementation details:

All AbbVie personnel with direct oversight of the conduct and management of the trial (with the exception of AbbVie's Drug Supply Management Team) the Investigator, study site personnel and the subject remained blinded to each subject's treatment throughout the blinded period of the study.

### Arms

|                              |                     |
|------------------------------|---------------------|
| Are arms mutually exclusive? | Yes                 |
| <b>Arm title</b>             | Period 1 Placebo IV |

Arm description:

Participants randomized to receive Placebo by intravenous (IV) infusion at Baseline, Weeks 4 and 8.

|  |                       |
|--|-----------------------|
| Arm type                               | Experimental          |
| Investigational medicinal product name | Period 1 Placebo IV   |
| Investigational medicinal product code |                       |
| Other name                             |                       |
| Pharmaceutical forms                   | Solution for infusion |
| Routes of administration               | Intravenous use       |

Dosage and administration details:

Participants received placebo intravenously at Baseline, Week 4 and Week 8.

|                  |                                |
|------------------|--------------------------------|
| <b>Arm title</b> | Period 1 Risankizumab 600mg IV |
|------------------|--------------------------------|

Arm description:

Participants randomized to receive risankizumab 600mg by intravenous infusion at Baseline, Weeks 4 and 8.

|  |                                |
|--|--------------------------------|
| Arm type                               | Experimental                   |
| Investigational medicinal product name | Period 1 Risankizumab 600mg IV |
| Investigational medicinal product code | ABBV-066                       |
| Other name                             | BI 655066, SKYRIZI             |
| Pharmaceutical forms                   | Solution for infusion          |
| Routes of administration               | Intravenous use                |

Dosage and administration details:

Participants received risankizumab 600mg intravenously at Baseline, Week 4 and Week 8.

|                  |                                 |
|------------------|---------------------------------|
| <b>Arm title</b> | Period 1 Risankizumab 1200mg IV |
|------------------|---------------------------------|

Arm description:

Participants randomized to receive risankizumab 1200mg by intravenous infusion at Baseline, Weeks 4

and 8.

|  |                                 |
|--|---------------------------------|
| Arm type                               | Experimental                    |
| Investigational medicinal product name | Period 1 Risankizumab 1200mg IV |
| Investigational medicinal product code | ABBV-066                        |
| Other name                             | BI 655066, SKYRIZI              |
| Pharmaceutical forms                   | Solution for infusion           |
| Routes of administration               | Intravenous use                 |

Dosage and administration details:

Participants received risankizumab 1200mg intravenously at Baseline, Week 4 and Week 8.

| Number of subjects in period 1   | Period 1 Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |
|----------------------------------|---------------------|--------------------------------------|---------------------------------------|
|                                  |                     |                                      |                                       |
| Started                          | 186                 | 373                                  | 372                                   |
| Completed                        | 163                 | 365                                  | 366                                   |
| Not completed                    | 23                  | 8                                    | 6                                     |
| Adverse event, non-fatal         | 13                  | 4                                    | 3                                     |
| Other, not specified             | 1                   | 1                                    | 2                                     |
| COVID-19 logistical restrictions | 2                   | -                                    | -                                     |
| Lack of efficacy                 | 3                   | -                                    | 1                                     |
| Withdrawal by subject            | 4                   | 3                                    | -                                     |

## Period 2

|                              |                              |
|------------------------------|------------------------------|
| Period 2 title               | Induction Period 2           |
| Is this the baseline period? | No                           |
| Allocation method            | Randomised - controlled      |
| Blinding used                | Double blind                 |
| Roles blinded                | Investigator, Carer, Subject |

Blinding implementation details:

All AbbVie personnel with direct oversight of the conduct and management of the trial (with the exception of AbbVie's Drug Supply Management Team) the Investigator, study site personnel and the subject remained blinded to each subject's treatment throughout the blinded period of the study.

## Arms

|                              |                                |
|------------------------------|--------------------------------|
| Are arms mutually exclusive? | Yes                            |
| Arm title                    | Period 2 Risankizumab 180mg SC |

Arm description:

Participants randomized to receive risankizumab 180mg by subcutaneous(SC) injection at Weeks 12 and 20.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|  |                                |
|--|--------------------------------|
| Investigational medicinal product name | Period 2 Risankizumab 180mg SC |
| Investigational medicinal product code | ABBV-066                       |
| Other name                             | BI 655066, SKYRIZI             |
| Pharmaceutical forms                   | Solution for injection         |
| Routes of administration               | Subcutaneous use               |

Dosage and administration details:

Participants received risankizumab 180mg subcutaneously at Weeks 12 and 20.

|                  |                                |
|------------------|--------------------------------|
| <b>Arm title</b> | Period 2 Risankizumab 360mg SC |
|------------------|--------------------------------|

Arm description:

Participants randomized to receive risankizumab 360mg by subcutaneous injection at Weeks 12 and 20.

|  |                                |
|--|--------------------------------|
| Arm type                               | Experimental                   |
| Investigational medicinal product name | Period 2 Risankizumab 360mg SC |
| Investigational medicinal product code | ABBV-066                       |
| Other name                             | BI 655066, SKYRIZI             |
| Pharmaceutical forms                   | Solution for injection         |
| Routes of administration               | Subcutaneous use               |

Dosage and administration details:

Participants received risankizumab 360mg subcutaneously at Weeks 12 and 20.

|                  |                                 |
|------------------|---------------------------------|
| <b>Arm title</b> | Period 2 Risankizumab 1200mg IV |
|------------------|---------------------------------|

Arm description:

Participants randomized to receive risankizumab 1200mg by intravenous infusion at Weeks 12, 16 and 20.

|  |                                 |
|--|---------------------------------|
| Arm type                               | Experimental                    |
| Investigational medicinal product name | Period 2 Risankizumab 1200mg IV |
| Investigational medicinal product code | ABBV-066                        |
| Other name                             | BI 655066, SKYRIZI              |
| Pharmaceutical forms                   | Solution for infusion           |
| Routes of administration               | Intravenous use                 |

Dosage and administration details:

Participants received risankizumab 1200mg intravenously at Weeks 12, 16, and 20.

|                  |   |
|------------------|---|
| <b>Arm title</b> | Period 2 Placebo/Risankizumab 1200mg IV |
|------------------|---|

Arm description:

Participants who received placebo in Induction Period 1 received 1200 mg risankizumab by intravenous infusion at Weeks 12, 16, and 20.

|  |   |
|--|---|
| Arm type                               | Experimental                            |
| Investigational medicinal product name | Period 2 Placebo/Risankizumab 1200mg IV |
| Investigational medicinal product code | ABBV-066                                |
| Other name                             | BI 655066, SKYRIZI                      |
| Pharmaceutical forms                   | Solution for infusion                   |
| Routes of administration               | Intravenous use                         |

Dosage and administration details:

Participants who received placebo in Induction Period 1 received 1200 mg risankizumab intravenously at Weeks 12, 16, and 20.

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Period 2<br>Risankizumab<br>180mg SC | Period 2<br>Risankizumab<br>360mg SC | Period 2<br>Risankizumab<br>1200mg IV |
|---|--------------------------------------|--------------------------------------|---------------------------------------|
| Started   | 67                                   | 68                                   | 67                                    |
| Completed   | 62                                   | 65                                   | 64                                    |
| Not completed                                       | 5                                    | 3                                    | 3                                     |
| Adverse event, non-fatal                            | -                                    | 2                                    | -                                     |
| Other, not specified                                | -                                    | -                                    | -                                     |
| COVID-19 logistical restrictions                    | 1                                    | -                                    | 2                                     |
| Lack of efficacy                                    | 2                                    | -                                    | 1                                     |
| Withdrawal by subject                               | 2                                    | 1                                    | -                                     |

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Period 2<br>Placebo/Risankizumab<br>1200mg IV |
|---|---|
| Started   | 76  |
| Completed   | 74  |
| Not completed                                       | 2   |
| Adverse event, non-fatal                            | -   |
| Other, not specified                                | 2   |
| COVID-19 logistical restrictions                    | -   |
| Lack of efficacy                                    | -   |
| Withdrawal by subject                               | -   |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: All participants who entered Induction Period 2.

## Baseline characteristics

### Reporting groups

|  |                                 |
|--|---------------------------------|
| Reporting group title  | Period 1 Placebo IV             |
| Reporting group description:   |                                 |
| Participants randomized to receive Placebo by intravenous (IV) infusion at Baseline, Weeks 4 and 8.        |                                 |
| Reporting group title  | Period 1 Risankizumab 600mg IV  |
| Reporting group description:   |                                 |
| Participants randomized to receive risankizumab 600mg by intravenous infusion at Baseline, Weeks 4 and 8.  |                                 |
| Reporting group title  | Period 1 Risankizumab 1200mg IV |
| Reporting group description:   |                                 |
| Participants randomized to receive risankizumab 1200mg by intravenous infusion at Baseline, Weeks 4 and 8. |                                 |

| Reporting group values             | Period 1 Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |
|------------------------------------|---------------------|--------------------------------------|---------------------------------------|
| Number of subjects                 | 186                 | 373                                  | 372                                   |
| Age categorical<br>Units: Subjects |                     |                                      |                                       |

|   |         |         |         |
|---|---------|---------|---------|
| Age continuous<br>Units: years            |         |         |         |
| arithmetic mean                           | 37.5    | 38.5    | 37.6    |
| standard deviation                        | ± 13.51 | ± 13.22 | ± 13.55 |
| Gender categorical<br>Units: Subjects     |         |         |         |
| Female                                    | 93      | 168     | 173     |
| Male                                      | 93      | 205     | 199     |
| Ethnicity<br>Units: Subjects              |         |         |         |
| Hispanic or Latino                        | 10      | 13      | 18      |
| Not Hispanic or Latino                    | 176     | 360     | 354     |
| Race<br>Units: Subjects                   |         |         |         |
| American Indian or Alaska Native          | 0       | 0       | 0       |
| Asian                                     | 32      | 68      | 75      |
| Black or African American                 | 9       | 10      | 13      |
| Native Hawaiian or Other Pacific Islander | 1       | 0       | 1       |
| White                                     | 144     | 291     | 279     |
| More than one race                        | 0       | 4       | 4       |

| Reporting group values             | Total |  |  |
|------------------------------------|-------|--|--|
| Number of subjects                 | 931   |  |  |
| Age categorical<br>Units: Subjects |       |  |  |



|   |     |  |  |
|---|-----|--|--|
| Age continuous<br>Units: years<br>arithmetic mean<br>standard deviation | -   |  |  |
| Gender categorical<br>Units: Subjects                                   |     |  |  |
| Female  | 434 |  |  |
| Male  | 497 |  |  |
| Ethnicity<br>Units: Subjects  |     |  |  |
| Hispanic or Latino  | 41  |  |  |
| Not Hispanic or Latino  | 890 |  |  |
| Race<br>Units: Subjects   |     |  |  |
| American Indian or Alaska Native  | 0   |  |  |
| Asian   | 175 |  |  |
| Black or African American   | 32  |  |  |
| Native Hawaiian or Other Pacific Islander                               | 2   |  |  |
| White   | 714 |  |  |
| More than one race  | 8   |  |  |

## End points

### End points reporting groups

|  |   |
|--|---|
| Reporting group title  | Period 1 Placebo IV                     |
| Reporting group description:<br>Participants randomized to receive Placebo by intravenous (IV) infusion at Baseline, Weeks 4 and 8.                                    |   |
| Reporting group title  | Period 1 Risankizumab 600mg IV          |
| Reporting group description:<br>Participants randomized to receive risankizumab 600mg by intravenous infusion at Baseline, Weeks 4 and 8.                              |   |
| Reporting group title  | Period 1 Risankizumab 1200mg IV         |
| Reporting group description:<br>Participants randomized to receive risankizumab 1200mg by intravenous infusion at Baseline, Weeks 4 and 8.                             |   |
| Reporting group title  | Period 2 Risankizumab 180mg SC          |
| Reporting group description:<br>Participants randomized to receive risankizumab 180mg by subcutaneous(SC) injection at Weeks 12 and 20.                                |   |
| Reporting group title  | Period 2 Risankizumab 360mg SC          |
| Reporting group description:<br>Participants randomized to receive risankizumab 360mg by subcutaneous injection at Weeks 12 and 20.                                    |   |
| Reporting group title  | Period 2 Risankizumab 1200mg IV         |
| Reporting group description:<br>Participants randomized to receive risankizumab 1200mg by intravenous infusion at Weeks 12, 16 and 20.                                 |   |
| Reporting group title  | Period 2 Placebo/Risankizumab 1200mg IV |
| Reporting group description:<br>Participants who received placebo in Induction Period 1 received 1200 mg risankizumab by intravenous infusion at Weeks 12, 16, and 20. |   |

### Primary: Percentage of Participants With Endoscopic Response at Week 12

|   |  |
|---|--|
| End point title   | Percentage of Participants With Endoscopic Response at Week 12 |
| End point description:<br>Endoscopic response was a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD) > 50% from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).<br><br>Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |  |
| End point type  | Primary  |
| End point timeframe:<br>Week 12   |  |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 12.0                   | 40.3                                 | 32.1                                  |  |

## Statistical analyses

| Statistical analysis title   | Statistical Analysis 1                               |
|--|--|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis  | 511  |
| Analysis specification   | Pre-specified  |
| Analysis type  | superiority  |
| P-value  | < 0.001  |
| Method   | Cochran-Mantel-Haenszel                              |
| Parameter estimate   | Adjusted risk difference                             |
| Point estimate   | 28.3   |
| Confidence interval  |  |
| level  | 95 %   |
| sides  | 2-sided  |
| lower limit  | 21.2   |
| upper limit  | 35.4   |

| Statistical analysis title   | Statistical Analysis 2                                |
|--|---|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 514   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 20.3  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 13.6  |
| upper limit  | 27.1  |

## Primary: Percentage of Participants With Clinical Remission at Week 12

|   |   |
|---|---|
| End point title   | Percentage of Participants With Clinical Remission at Week 12 |
| End point description:  |   |
| Clinical remission is defined as using the average daily Stool Frequency (SF) $\leq 2.8$ and not worse than Baseline AND average daily Abdominal Pain (AP) score $\leq 1$ and not worse than Baseline.  |   |
| Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |   |
| End point type  | Primary   |
| End point timeframe:  |   |
| Week 12   |   |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 21.7                   | 43.5                                 | 41.0                                  |  |

## Statistical analyses

|   |  |
|---|--|
| Statistical analysis title                  | Statistical Analysis 1                               |
| Statistical analysis description:           |  |
| Risk difference = (risankizumab - placebo). |  |
| Comparison groups                           | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis     | 511  |
| Analysis specification                      | Pre-specified  |
| Analysis type                               | superiority  |
| P-value                                     | < 0.001  |
| Method                                      | Cochran-Mantel-Haenszel                              |
| Parameter estimate                          | Adjusted risk difference                             |
| Point estimate                              | 21.9   |
| Confidence interval                         |  |
| level                                       | 95 %   |
| sides                                       | 2-sided  |
| lower limit                                 | 13.8   |
| upper limit                                 | 29.9   |

|   |   |
|---|---|
| Statistical analysis title                  | Statistical Analysis 2                                |
| Statistical analysis description:           |   |
| Risk difference = (risankizumab - placebo). |   |
| Comparison groups                           | Period 1 Placebo IV v Period 1 Risankizumab 1200mg IV |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 514                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 18.8                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 10.8                     |
| upper limit                             | 26.8                     |

## Secondary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission at Week 12

|   |   |
|---|---|
| End point title   | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Remission at Week 12 |
| End point description:<br>Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. Clinical remission of Crohn's disease is defined as CDAI < 150.   |   |
| Intent to Treat IA Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible Simple Endoscopic Score for Crohn's disease (SES-CD) of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |   |
| End point type  | Secondary   |
| End point timeframe:<br>Week 12   |   |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: Percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 24.6                   | 45.2                                 | 41.6                                  |  |

## Statistical analyses

|  |  |
|--|--|
| Statistical analysis title   | Statistical Analysis 1                               |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 511                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 20.7                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 12.4                     |
| upper limit                             | 29                       |

|  |   |
|--|---|
| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 514   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 16.7  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 8.5   |
| upper limit  | 24.9  |

## Secondary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response at Week 12

|  |  |
|--|--|
| End point title  | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response at Week 12 |
| End point description:<br>Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. Clinical response is defined as reduction of CDAI $\geq$ 100 points from baseline. |  |
| Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq$ 6 ( $\geq$ 4 for isolated ileal disease) excluding the narrowing component.          |  |
| End point type   | Secondary  |
| End point timeframe:<br>Week 12  |  |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 36.7                   | 59.7                                 | 64.9                                  |  |

## Statistical analyses

| Statistical analysis title   | Statistical Analysis 1                               |
|--|--|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis  | 511  |
| Analysis specification   | Pre-specified  |
| Analysis type  | superiority  |
| P-value  | < 0.001  |
| Method   | Cochran-Mantel-Haenszel                              |
| Parameter estimate   | Adjusted risk difference                             |
| Point estimate   | 23.1   |
| Confidence interval  |  |
| level  | 95 %   |
| sides  | 2-sided  |
| lower limit  | 14.2   |
| upper limit  | 31.9   |

| Statistical analysis title   | Statistical Analysis 2                                |
|--|---|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 514   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 27.7  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 19  |
| upper limit  | 36.4  |

## Secondary: Change From Baseline of Induction in Functional Assessment of Chronic

## Illness Therapy (FACIT)-Fatigue at Week 12

|                 |  |
|-----------------|--|
| End point title | Change From Baseline of Induction in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at Week 12 |
|-----------------|--|

End point description:

The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four point Likert scale. The FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 12              |           |

| End point values                    | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-------------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                  | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed         | 134                    | 302                                  | 310                                   |  |
| Units: units on a scale             |                        |                                      |                                       |  |
| least squares mean (standard error) | 6.0 ( $\pm$ 0.86)      | 11.2 ( $\pm$ 0.59)                   | 10.1 ( $\pm$ 0.58)                    |  |

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Mean difference = (risankizumab - placebo).

|   |  |
|---|--|
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis | 436  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Mixed-Effect Model Repeat Measurement                |
| Parameter estimate                      | LS Mean  |
| Point estimate                          | 5.2  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 3.2  |
| upper limit                             | 7.2  |

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 2 |
|----------------------------|------------------------|



Statistical analysis description:

Mean difference = (risankizumab - placebo).

|   |   |
|---|---|
| Comparison groups                       | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis | 444   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Mixed-Effect Model Repeat Measurement                 |
| Parameter estimate                      | LS Mean   |
| Point estimate                          | 4.1   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 2.1   |
| upper limit                             | 6.1   |

## Secondary: Percentage of Participants With Enhanced Clinical Response and Endoscopic Response at Week 12

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants With Enhanced Clinical Response and Endoscopic Response at Week 12 |
|-----------------|---|

End point description:

Enhanced clinical response was defined as  $\geq 60\%$  decrease in average daily Stool Frequency and/or  $\geq 35\%$  decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission. Endoscopic Response was defined as a decrease in Simplified Endoscopic Score for Crohn's Disease (SES-CD)  $> 50\%$  from Baseline (or for subjects with isolated ileal disease and a Baseline SES-CD of 4, at least a 2 point reduction from Baseline).

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 12              |           |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 8                      | 30.9                                 | 23.2                                  |  |

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|   |  |
|---|--|
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis | 511  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel                              |
| Parameter estimate                      | Adjusted risk difference                             |
| Point estimate                          | 23.2   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 16.8   |
| upper limit                             | 29.6   |

|                                   |                        |
|-----------------------------------|------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|   |   |
|---|---|
| Comparison groups                       | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis | 514   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel                               |
| Parameter estimate                      | Adjusted risk difference                              |
| Point estimate                          | 15.2  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 9.3   |
| upper limit                             | 21.2  |

## Secondary: Percentage of Participants With Endoscopic Remission at Week 12

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants With Endoscopic Remission at Week 12 |
|-----------------|---|

End point description:

Endoscopic remission was defined as SES-CD  $\leq 4$  and at least a 2-point reduction versus baseline and no subscore greater than 1 in any individual variable.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| <b>End point values</b>           | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 9.1                    | 24.2                                 | 23.9                                  |  |

## Statistical analyses

| <b>Statistical analysis title</b>  | Statistical Analysis 1                               |
|--|--|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis  | 511  |
| Analysis specification   | Pre-specified  |
| Analysis type  | superiority  |
| P-value  | < 0.001  |
| Method   | Cochran-Mantel-Haenszel                              |
| Parameter estimate   | Adjusted risk difference                             |
| Point estimate   | 15.1   |
| Confidence interval  |  |
| level  | 95 %   |
| sides  | 2-sided  |
| lower limit  | 9  |
| upper limit  | 21.2   |

| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
|--|---|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 514   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 15.4  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 9.4   |
| upper limit  | 21.4  |

**Secondary: Percentage of Participants With Enhanced Clinical Response at Week 12**

|                 |   |
|-----------------|---|
| End point title | Percentage of Participants With Enhanced Clinical Response at Week 12 |
|-----------------|---|

End point description:

Enhanced clinical response was defined as  $\geq 60\%$  decrease in average daily Stool Frequency and/or  $\geq 35\%$  decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 12              |           |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 41.9                   | 62.8                                 | 64.3                                  |  |

**Statistical analyses**

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|   |  |
|---|--|
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis | 511  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel                              |
| Parameter estimate                      | Adjusted risk difference                             |
| Point estimate                          | 21   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 12.2   |
| upper limit                             | 29.9   |

|  |   |
|--|---|
| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 514   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 21.6  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 12.8  |
| upper limit  | 30.4  |

### Secondary: Percentage of Participants With Ulcer-Free Endoscopy at Week 12

|  |   |
|--|---|
| End point title  | Percentage of Participants With Ulcer-Free Endoscopy at Week 12 |
| End point description:<br>Ulcer-free endoscopy was defined as SES-CD ulcerated surface subscore of 0 in subjects with SES-CD ulcerated surface subscore $\geq 1$ at baseline.<br><br>Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 12  |   |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 173                    | 336                                  | 338                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 7.6                    | 21.0                                 | 16.4                                  |  |

### Statistical analyses

|  |  |
|--|--|
| <b>Statistical analysis title</b>  | Statistical Analysis 1                               |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 509                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 13.7                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 7.9                      |
| upper limit                             | 19.5                     |

|  |   |
|--|---|
| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 511   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 9.1   |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 3.7   |
| upper limit  | 14.5  |

|   |  |
|---|--|
| <b>Secondary: Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline</b>  |  |
| End point title   | Percentage of Participants With Resolution of Extra-Intestinal Manifestations (EIMs) at Week 12, in Participants With EIMs at Baseline |
| End point description:<br>Manifestations of Crohn's disease in areas of the body other than the digestive tract, including eyes, skin, joints, mouth, and liver.  |  |
| Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 12   |  |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 64                     | 140                                  | 158                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 20.5                   | 38.1                                 | 43.7                                  |  |

## Statistical analyses

| Statistical analysis title   | Statistical Analysis 1                               |
|--|--|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |  |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis  | 204  |
| Analysis specification   | Pre-specified  |
| Analysis type  | superiority  |
| P-value  | = 0.022  |
| Method   | Cochran-Mantel-Haenszel                              |
| Parameter estimate   | Adjusted risk difference                             |
| Point estimate   | 14.6   |
| Confidence interval  |  |
| level  | 95 %   |
| sides  | 2-sided  |
| lower limit  | 2.1  |
| upper limit  | 27   |

| Statistical analysis title   | Statistical Analysis 2                                |
|--|---|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 222   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | = 0.001   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 23.7  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 11.1  |
| upper limit  | 36.3  |

## Secondary: Percentage of Participants With CD-Related Hospitalization through

**Week 12**

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants With CD-Related Hospitalization through Week 12 |
|-----------------|--|

End point description:

Participants with at least one admission to the hospital due to Crohn's Disease

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 12                     | 3.3                                  | 1.8                                   |  |

**Statistical analyses**

|                                   |                        |
|-----------------------------------|------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 1 |
|-----------------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|                   |  |
|-------------------|--|
| Comparison groups | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
|-------------------|--|

|   |     |
|---|-----|
| Number of subjects included in analysis | 511 |
|---|-----|

|                        |               |
|------------------------|---------------|
| Analysis specification | Pre-specified |
|------------------------|---------------|

|               |             |
|---------------|-------------|
| Analysis type | superiority |
|---------------|-------------|

|         |         |
|---------|---------|
| P-value | < 0.001 |
|---------|---------|

|        |                         |
|--------|-------------------------|
| Method | Cochran-Mantel-Haenszel |
|--------|-------------------------|

|                    |                          |
|--------------------|--------------------------|
| Parameter estimate | Adjusted risk difference |
|--------------------|--------------------------|

|                |      |
|----------------|------|
| Point estimate | -8.7 |
|----------------|------|

Confidence interval

|       |      |
|-------|------|
| level | 95 % |
|-------|------|

|       |         |
|-------|---------|
| sides | 2-sided |
|-------|---------|

|             |       |
|-------------|-------|
| lower limit | -13.9 |
|-------------|-------|

|             |      |
|-------------|------|
| upper limit | -3.5 |
|-------------|------|

|                                   |                        |
|-----------------------------------|------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|                   |   |
|-------------------|---|
| Comparison groups | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
|-------------------|---|



|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 514                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | -10.2                    |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | -15.2                    |
| upper limit                             | -5.2                     |

### Secondary: Percentage of Participants Without Draining Fistulas at Week 12 in Participants With Draining Fistulas at Baseline

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants Without Draining Fistulas at Week 12 in Participants With Draining Fistulas at Baseline |
|-----------------|--|

End point description:

Participants without draining fistulas at Week 12 in participants who had draining fistulas at baseline.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 9                      | 18                                   | 24                                    |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 22.2                   | 27.8                                 | 29.2                                  |  |

### Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo).

|                   |  |
|-------------------|--|
| Comparison groups | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
|-------------------|--|

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 27                       |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 1                      |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 5.6                      |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | -28.6                    |
| upper limit                             | 39.7                     |

|  |   |
|--|---|
| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis  | 33  |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | = 1   |
| Method   | Cochran-Mantel-Haenszel                               |
| Parameter estimate   | Adjusted risk difference                              |
| Point estimate   | 6.9   |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | -25.7   |
| upper limit  | 39.6  |

## Secondary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response at Week 4

|  |   |
|--|---|
| End point title  | Percentage of Participants With Crohn's Disease Activity Index (CDAI) Clinical Response at Week 4 |
| End point description:<br>Crohn's Disease Activity Index (CDAI) is used to assess the symptoms of participants with Crohn's Disease. Higher CDAI scores indicate more severe disease. Clinical response is defined as reduction of CDAI $\geq$ 100 points from baseline. |   |
| Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq$ 6 ( $\geq$ 4 for isolated ileal disease) excluding the narrowing component.          |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 4   |   |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 25.2                   | 40.8                                 | 37.2                                  |  |

## Statistical analyses

| Statistical analysis title  | Statistical Analysis 1                               |
|---|--|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo) |  |
| Comparison groups   | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis   | 511  |
| Analysis specification  | Pre-specified  |
| Analysis type   | superiority  |
| P-value   | < 0.001  |
| Method  | Cochran-Mantel-Haenszel                              |
| Parameter estimate  | Adjusted risk difference                             |
| Point estimate  | 15.4   |
| Confidence interval   |  |
| level   | 95 %   |
| sides   | 2-sided  |
| lower limit   | 7.2  |
| upper limit   | 23.7   |

| Statistical analysis title  | Statistical Analysis 2                                |
|---|---|
| Statistical analysis description:<br>Risk difference = (risankizumab - placebo) |   |
| Comparison groups   | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis   | 514   |
| Analysis specification  | Pre-specified   |
| Analysis type   | superiority   |
| P-value   | = 0.007   |
| Method  | Cochran-Mantel-Haenszel                               |
| Parameter estimate  | Adjusted risk difference                              |
| Point estimate  | 11.2  |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided   |
| lower limit   | 3.1   |
| upper limit   | 19.2  |

## Secondary: Percentage of Participants With Enhanced Clinical Response at Week 4

|                 |  |
|-----------------|--|
| End point title | Percentage of Participants With Enhanced Clinical Response at Week 4 |
|-----------------|--|

End point description:

Enhanced clinical response was defined as  $\geq 60\%$  decrease in average daily Stool Frequency and/or  $\geq 35\%$  decrease in average daily Abdominal Pain score and both not worse than baseline, and/or clinical remission.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 4

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 31                     | 46                                   | 43.4                                  |  |

## Statistical analyses

|                                   |                        |
|-----------------------------------|------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 1 |
|-----------------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo)

|   |  |
|---|--|
| Comparison groups                       | Period 1 Risankizumab 600mg IV v Period 1 Placebo IV |
| Number of subjects included in analysis | 511  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel                              |
| Parameter estimate                      | Adjusted risk difference                             |
| Point estimate                          | 14.9   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 6.2  |
| upper limit                             | 23.5   |

|                                   |                        |
|-----------------------------------|------------------------|
| <b>Statistical analysis title</b> | Statistical Analysis 2 |
|-----------------------------------|------------------------|

Statistical analysis description:

Risk difference = (risankizumab - placebo)

|                   |   |
|-------------------|---|
| Comparison groups | Period 1 Risankizumab 1200mg IV v Period 1 Placebo IV |
|-------------------|---|

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 514                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | = 0.007                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 11.8                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 3.2                      |
| upper limit                             | 20.3                     |

## Secondary: Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12

|                 |  |
|-----------------|--|
| End point title | Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) total score at Week 12 |
|-----------------|--|

End point description:

The IBDQ is a 32-item (ranges 1 – 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). The IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 12

| End point values                    | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-------------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                  | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed         | 134                    | 302                                  | 310                                   |  |
| Units: units on a scale             |                        |                                      |                                       |  |
| least squares mean (standard error) | 23.6 ( $\pm$ 2.72)     | 44.3 ( $\pm$ 1.87)                   | 43 ( $\pm$ 1.85)                      |  |

## Statistical analyses

|                            |                        |
|----------------------------|------------------------|
| Statistical analysis title | Statistical Analysis 1 |
|----------------------------|------------------------|

Statistical analysis description:

Mean difference = (risankizumab - placebo).

|                   |  |
|-------------------|--|
| Comparison groups | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
|-------------------|--|

|   |                                       |
|---|---------------------------------------|
| Number of subjects included in analysis | 436                                   |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority                           |
| P-value                                 | < 0.001                               |
| Method                                  | Mixed-Effect Model Repeat Measurement |
| Parameter estimate                      | LS Mean                               |
| Point estimate                          | 20.7                                  |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | 14.3                                  |
| upper limit                             | 27.1                                  |

|  |   |
|--|---|
| <b>Statistical analysis title</b>  | Statistical Analysis 2                                |
| Statistical analysis description:<br>Mean difference = (risankizumab - placebo). |   |
| Comparison groups  | Period 1 Placebo IV v Period 1 Risankizumab 1200mg IV |
| Number of subjects included in analysis  | 444   |
| Analysis specification   | Pre-specified   |
| Analysis type  | superiority   |
| P-value  | < 0.001   |
| Method   | Mixed-Effect Model Repeat Measurement                 |
| Parameter estimate   | LS Mean   |
| Point estimate   | 19.4  |
| Confidence interval  |   |
| level  | 95 %  |
| sides  | 2-sided   |
| lower limit  | 13.1  |
| upper limit  | 25.8  |

## **Secondary: Change from baseline in Work Productivity and Impairment Questionnaire – Crohn's disease (WPAI-CD) Overall Work Impairment at Week 12**

|                 |   |
|-----------------|---|
| End point title | Change from baseline in Work Productivity and Impairment Questionnaire – Crohn's disease (WPAI-CD) Overall Work Impairment at Week 12 |
|-----------------|---|

End point description:

WPAI: CD is a questionnaire used to evaluate lost productivity due to CD ; scores are presented as percentages (multiplying the scores by 100), with 0% representing no impact on productivity and 100% representing complete impact on productivity. Total work productivity impairment takes into account both hours missed due to CD symptoms and the patient's assessment of the degree to which CD affected their productivity while working (overall work impairment [OWI]). WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                                 |           |
|---------------------------------|-----------|
| End point type                  | Secondary |
| End point timeframe:<br>Week 12 |           |

| <b>End point values</b>             | Period 1<br>Placebo IV    | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-------------------------------------|---------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                  | Reporting group           | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed         | 65                        | 156                                  | 162                                   |  |
| Units: units on a scale             |                           |                                      |                                       |  |
| least squares mean (standard error) | -8.344 ( $\pm$<br>3.5640) | -17.930 ( $\pm$<br>2.3446)           | -20.485 ( $\pm$<br>2.3112)            |  |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                               |
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis | 221  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.024  |
| Method                                  | Mixed-Effect Model Repeat Measurement                |
| Parameter estimate                      | LS Mean  |
| Point estimate                          | -9.586   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | -17.89   |
| upper limit                             | -1.282   |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2                                |
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 1200mg IV |
| Number of subjects included in analysis | 227   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | = 0.004   |
| Method                                  | Mixed-Effect Model Repeat Measurement                 |
| Parameter estimate                      | LS Mean   |
| Point estimate                          | -12.141   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | -20.39  |
| upper limit                             | -3.892  |

## Secondary: Change from baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) score at Week 12

|                 |   |
|-----------------|---|
| End point title | Change from baseline in Short Form-36 (SF-36) Physical Component Summary (PCS) score at Week 12 |
|-----------------|---|

### End point description:

The Short Form-36 Health Survey determined participants' overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of  $\geq 6$  ( $\geq 4$  for isolated ileal disease) excluding the narrowing component.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

### End point timeframe:

Week 12

| End point values                    | Period 1<br>Placebo IV   | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-------------------------------------|--------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                  | Reporting group          | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed         | 134                      | 302                                  | 309                                   |  |
| Units: units on a scale             |                          |                                      |                                       |  |
| least squares mean (standard error) | 5.482 ( $\pm$<br>0.5985) | 8.394 ( $\pm$<br>0.4107)             | 8.756 ( $\pm$<br>0.4071)              |  |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1                               |
| Comparison groups                       | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |
| Number of subjects included in analysis | 436  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Mixed-Effect Model Repeat Measurement                |
| Parameter estimate                      | LS Mean  |
| Point estimate                          | 2.913  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 1.512  |
| upper limit                             | 4.313  |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Statistical Analysis 2                                |
| Comparison groups                 | Period 1 Placebo IV v Period 1 Risankizumab 1200mg IV |



|   |                                       |
|---|---------------------------------------|
| Number of subjects included in analysis | 443                                   |
| Analysis specification                  | Pre-specified                         |
| Analysis type                           | superiority                           |
| P-value                                 | < 0.001                               |
| Method                                  | Mixed-Effect Model Repeat Measurement |
| Parameter estimate                      | LS Mean                               |
| Point estimate                          | 3.275                                 |
| Confidence interval                     |                                       |
| level                                   | 95 %                                  |
| sides                                   | 2-sided                               |
| lower limit                             | 1.877                                 |
| upper limit                             | 4.672                                 |

## Secondary: Percentage of Participants With Clinical Remission at Week 4

|   |  |
|---|--|
| End point title   | Percentage of Participants With Clinical Remission at Week 4 |
| End point description:  |  |
| Clinical remission is defined as using the average daily Stool Frequency (SF) $\leq 2.8$ and not worse than Baseline AND average daily Abdominal Pain (AP) score $\leq 1$ and not worse than Baseline.  |  |
| Intent to Treat 1A Population: all randomized subjects who received at least one dose of study drug during the 12-Week Induction Period, and had baseline eligible SES-CD of $\geq 6$ ( $\geq 4$ for isolated ileal disease) excluding the narrowing component. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Week 4  |  |

| End point values                  | Period 1<br>Placebo IV | Period 1<br>Risankizumab<br>600mg IV | Period 1<br>Risankizumab<br>1200mg IV |  |
|-----------------------------------|------------------------|--------------------------------------|---------------------------------------|--|
| Subject group type                | Reporting group        | Reporting group                      | Reporting group                       |  |
| Number of subjects analysed       | 175                    | 336                                  | 339                                   |  |
| Units: percentage of participants |                        |                                      |                                       |  |
| number (not applicable)           | 9.1                    | 21.0                                 | 21.2                                  |  |

## Statistical analyses

|   |  |
|---|--|
| Statistical analysis title                  | Statistical Analysis 1                               |
| Statistical analysis description:           |  |
| Risk difference = (risankizumab - placebo). |  |
| Comparison groups                           | Period 1 Placebo IV v Period 1 Risankizumab 600mg IV |

|   |                          |
|---|--------------------------|
| Number of subjects included in analysis | 511                      |
| Analysis specification                  | Pre-specified            |
| Analysis type                           | superiority              |
| P-value                                 | < 0.001                  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted risk difference |
| Point estimate                          | 11.5                     |
| Confidence interval                     |                          |
| level                                   | 95 %                     |
| sides                                   | 2-sided                  |
| lower limit                             | 5.4                      |
| upper limit                             | 17.5                     |

|   |   |
|---|---|
| <b>Statistical analysis title</b>           | Statistical Analysis 2                                |
| Statistical analysis description:           |   |
| Risk difference = (risankizumab - placebo). |   |
| Comparison groups                           | Period 1 Placebo IV v Period 1 Risankizumab 1200mg IV |
| Number of subjects included in analysis     | 514   |
| Analysis specification                      | Pre-specified   |
| Analysis type                               | superiority   |
| P-value                                     | < 0.001   |
| Method                                      | Cochran-Mantel-Haenszel                               |
| Parameter estimate                          | Adjusted risk difference                              |
| Point estimate                              | 11.7  |
| Confidence interval                         |   |
| level                                       | 95 %  |
| sides                                       | 2-sided   |
| lower limit                                 | 5.7   |
| upper limit                                 | 17.8  |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug until 140 days following last dose of study drug.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 23.1 |
|--------------------|------|

### Reporting groups

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Period 1 Risankizumab 1200mg IV |
|-----------------------|---------------------------------|

Reporting group description:

Participants randomized to receive risankizumab 1200mg by intravenous infusion at Baseline, Weeks 4 and 8.

|                       |                     |
|-----------------------|---------------------|
| Reporting group title | Period 1 Placebo IV |
|-----------------------|---------------------|

Reporting group description:

Participants randomized to receive Placebo intravenous by intravenous infusion at Baseline, Weeks 4 and 8.

|                       |                                |
|-----------------------|--------------------------------|
| Reporting group title | Period 1 Risankizumab 600mg IV |
|-----------------------|--------------------------------|

Reporting group description:

Participants randomized to receive risankizumab 600mg by intravenous infusion at Baseline, Weeks 4 and 8.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Period 1 Risankizumab total |
|-----------------------|-----------------------------|

Reporting group description: -

|                       |                                |
|-----------------------|--------------------------------|
| Reporting group title | Period 2 Risankizumab 360mg SC |
|-----------------------|--------------------------------|

Reporting group description:

Participants randomized to receive risankizumab 360mg by subcutaneous injection at Weeks 12 and 20.

|                       |                                |
|-----------------------|--------------------------------|
| Reporting group title | Period 2 Risankizumab 180mg SC |
|-----------------------|--------------------------------|

Reporting group description:

Participants randomized to receive risankizumab 180mg by subcutaneous injection at Weeks 12 and 20.

|                       |                                 |
|-----------------------|---------------------------------|
| Reporting group title | Period 2 Risankizumab 1200mg IV |
|-----------------------|---------------------------------|

Reporting group description:

Participants received risankizumab 1200mg by intravenous infusion at Weeks 12, 16, and 20.

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Period 2 Risankizumab total |
|-----------------------|-----------------------------|

Reporting group description: -

|                       |   |
|-----------------------|---|
| Reporting group title | Period 2 Placebo/Risankizumab 1200mg IV |
|-----------------------|---|

Reporting group description:

Participants who received placebo in Induction Period 1 received 1200 mg risankizumab by intravenous infusion at Weeks 12, 16, and 20.

| Serious adverse events                            | Period 1<br>Risankizumab<br>1200mg IV | Period 1 Placebo IV | Period 1<br>Risankizumab<br>600mg IV |
|---|---------------------------------------|---------------------|--------------------------------------|
| Total subjects affected by serious adverse events |                                       |                     |                                      |
| subjects affected / exposed                       | 14 / 372 (3.76%)                      | 28 / 186 (15.05%)   | 27 / 373 (7.24%)                     |
| number of deaths (all causes)                     | 0                                     | 2                   | 0                                    |
| number of deaths resulting from adverse events    | 0                                     | 2                   | 0                                    |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| Vascular disorders                                   |                 |                 |                 |
| DEEP VEIN THROMBOSIS                                 |                 |                 |                 |
| subjects affected / exposed                          | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| HYPERTENSION   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Surgical and medical procedures                      |                 |                 |                 |
| ABORTION INDUCED                                     |                 |                 |                 |
| subjects affected / exposed                          | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| General disorders and administration site conditions |                 |                 |                 |
| ASTHENIA   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| SYSTEMIC INFLAMMATORY RESPONSE SYNDROME              |                 |                 |                 |
| subjects affected / exposed                          | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all      | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                              |                 |                 |                 |
| FOOD ALLERGY   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                 |
| ASTHMA   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| PULMONARY EMBOLISM                                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                           | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Psychiatric disorders</b>                          |                 |                 |                 |
| <b>MENTAL DISORDER</b>                                |                 |                 |                 |
| subjects affected / exposed                           | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>OBSESSIVE-COMPULSIVE DISORDER</b>                  |                 |                 |                 |
| subjects affected / exposed                           | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Investigations</b>                                 |                 |                 |                 |
| <b>BODY TEMPERATURE INCREASED</b>                     |                 |                 |                 |
| subjects affected / exposed                           | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>HAEMOGLOBIN DECREASED</b>                          |                 |                 |                 |
| subjects affected / exposed                           | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>WEIGHT DECREASED</b>                               |                 |                 |                 |
| subjects affected / exposed                           | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Injury, poisoning and procedural complications</b> |                 |                 |                 |
| <b>FALL</b>   |                 |                 |                 |
| subjects affected / exposed                           | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>FOREARM FRACTURE</b>                               |                 |                 |                 |
| subjects affected / exposed                           | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all       | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all            | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Cardiac disorders                               |                 |                 |                 |
| VENTRICULAR TACHYCARDIA                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| DIZZINESS                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| SYNCOPE   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| ANAEMIA   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                 |                 |                 |
| RETINAL DISORDER                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| ABDOMINAL HERNIA                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| ABDOMINAL PAIN                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 2 / 186 (1.08%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 3           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| COLITIS   |                 |                 |                 |

|   |                 |                  |                 |
|---|-----------------|------------------|-----------------|
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%)  | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| CROHN'S DISEASE                                 |                 |                  |                 |
| subjects affected / exposed                     | 2 / 372 (0.54%) | 15 / 186 (8.06%) | 5 / 373 (1.34%) |
| occurrences causally related to treatment / all | 1 / 2           | 2 / 16           | 0 / 7           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| DIARRHOEA                                       |                 |                  |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%)  | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| GASTROINTESTINAL HAEMORRHAGE                    |                 |                  |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%)  | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| GASTROINTESTINAL INFLAMMATION                   |                 |                  |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%)  | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| GASTROINTESTINAL NECROSIS                       |                 |                  |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%)  | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1            | 0 / 0           |
| ILEAL PERFORATION                               |                 |                  |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%)  | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1            | 0 / 0           |
| ILEAL STENOSIS                                  |                 |                  |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%)  | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| ILEUS   |                 |                  |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 2 / 373 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| INTESTINAL ISCHAEMIA                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| INTESTINAL OBSTRUCTION                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 2 / 186 (1.08%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 2           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| INTESTINAL STENOSIS                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 2 / 186 (1.08%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| LARGE INTESTINE PERFORATION                     |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| NAUSEA  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| PANCREATITIS ACUTE                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| SMALL INTESTINAL OBSTRUCTION                    |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 1 / 186 (0.54%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| SUBILEUS  |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| TERMINAL ILEITIS                                |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| VOMITING  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| BILE DUCT STONE                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| CHOLANGITIS                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| CHOLECYSTITIS ACUTE                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| HEPATIC FUNCTION ABNORMAL                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| LIVER DISORDER                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| RASH  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| CALCULUS URINARY                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| HYDRONEPHROSIS                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| NEPHROLITHIASIS                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| URETEROLITHIASIS                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 2 / 373 (0.54%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| ANKYLOSING SPONDYLITIS                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| ARTHRALGIA                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| FIBROMYALGIA                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| FISTULA   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| SPONDYLITIS                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| ABDOMINAL WALL ABSCESS                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| ABSCESS INTESTINAL                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| ANAL ABSCESS                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| APPENDICITIS                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| GASTROENTERITIS                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| GASTROENTERITIS NOROVIRUS                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| LEPTOSPIROSIS                                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| LOWER RESPIRATORY TRACT INFECTION               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 1 / 373 (0.27%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| PERITONITIS                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| PNEUMONIA                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| PULMONARY SEPSIS                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| PYELONEPHRITIS                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| TONSILLITIS                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| URINARY TRACT INFECTION                         |                 |                 |                 |
| subjects affected / exposed                     | 1 / 372 (0.27%) | 0 / 186 (0.00%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| VULVAL CELLULITIS                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 372 (0.00%) | 1 / 186 (0.54%) | 0 / 373 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                        | Period 1<br>Risankizumab total | Period 2<br>Risankizumab<br>360mg SC | Period 2<br>Risankizumab<br>180mg SC |
|--|--------------------------------|--------------------------------------|--------------------------------------|
| Total subjects affected by serious adverse events    |                                |                                      |                                      |
| subjects affected / exposed                          | 41 / 745 (5.50%)               | 3 / 68 (4.41%)                       | 3 / 67 (4.48%)                       |
| number of deaths (all causes)                        | 0                              | 0                                    | 0                                    |
| number of deaths resulting from adverse events       | 0                              | 0                                    | 0                                    |
| Vascular disorders                                   |                                |                                      |                                      |
| DEEP VEIN THROMBOSIS                                 |                                |                                      |                                      |
| subjects affected / exposed                          | 1 / 745 (0.13%)                | 0 / 68 (0.00%)                       | 0 / 67 (0.00%)                       |
| occurrences causally related to treatment / all      | 0 / 1                          | 0 / 0                                | 0 / 0                                |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| HYPERTENSION   |                                |                                      |                                      |
| subjects affected / exposed                          | 1 / 745 (0.13%)                | 0 / 68 (0.00%)                       | 0 / 67 (0.00%)                       |
| occurrences causally related to treatment / all      | 0 / 1                          | 0 / 0                                | 0 / 0                                |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| Surgical and medical procedures                      |                                |                                      |                                      |
| ABORTION INDUCED                                     |                                |                                      |                                      |
| subjects affected / exposed                          | 1 / 745 (0.13%)                | 0 / 68 (0.00%)                       | 0 / 67 (0.00%)                       |
| occurrences causally related to treatment / all      | 0 / 1                          | 0 / 0                                | 0 / 0                                |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| General disorders and administration site conditions |                                |                                      |                                      |
| ASTHENIA   |                                |                                      |                                      |
| subjects affected / exposed                          | 0 / 745 (0.00%)                | 0 / 68 (0.00%)                       | 0 / 67 (0.00%)                       |
| occurrences causally related to treatment / all      | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| SYSTEMIC INFLAMMATORY RESPONSE SYNDROME              |                                |                                      |                                      |
| subjects affected / exposed                          | 1 / 745 (0.13%)                | 0 / 68 (0.00%)                       | 0 / 67 (0.00%)                       |
| occurrences causally related to treatment / all      | 1 / 1                          | 0 / 0                                | 0 / 0                                |
| deaths causally related to treatment / all           | 0 / 0                          | 0 / 0                                | 0 / 0                                |
| Immune system disorders                              |                                |                                      |                                      |
| FOOD ALLERGY   |                                |                                      |                                      |

|  |                 |                |                |
|--|-----------------|----------------|----------------|
| subjects affected / exposed                            | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Respiratory, thoracic and mediastinal disorders</b> |                 |                |                |
| <b>ASTHMA</b>  |                 |                |                |
| subjects affected / exposed                            | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>PULMONARY EMBOLISM</b>                              |                 |                |                |
| subjects affected / exposed                            | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Psychiatric disorders</b>                           |                 |                |                |
| <b>MENTAL DISORDER</b>                                 |                 |                |                |
| subjects affected / exposed                            | 0 / 745 (0.00%) | 1 / 68 (1.47%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>OBSESSIVE-COMPULSIVE DISORDER</b>                   |                 |                |                |
| subjects affected / exposed                            | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>Investigations</b>                                  |                 |                |                |
| <b>BODY TEMPERATURE INCREASED</b>                      |                 |                |                |
| subjects affected / exposed                            | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>HAEMOGLOBIN DECREASED</b>                           |                 |                |                |
| subjects affected / exposed                            | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>WEIGHT DECREASED</b>                                |                 |                |                |
| subjects affected / exposed                            | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all        | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all             | 0 / 0           | 0 / 0          | 0 / 0          |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| Injury, poisoning and procedural complications  |                 |                |                |
| FALL  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| FOREARM FRACTURE                                |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                 |                |                |
| VENTRICULAR TACHYCARDIA                         |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Nervous system disorders                        |                 |                |                |
| DIZZINESS                                       |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| SYNCOPE   |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Blood and lymphatic system disorders            |                 |                |                |
| ANAEMIA   |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Eye disorders                                   |                 |                |                |
| RETINAL DISORDER                                |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                 |                |                |
| ABDOMINAL HERNIA                                |                 |                |                |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ABDOMINAL PAIN                                  |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| COLITIS   |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| CROHN'S DISEASE                                 |                 |                |                |
| subjects affected / exposed                     | 7 / 745 (0.94%) | 0 / 68 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 1 / 9           | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| DIARRHOEA                                       |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| GASTROINTESTINAL HAEMORRHAGE                    |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| GASTROINTESTINAL INFLAMMATION                   |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| GASTROINTESTINAL NECROSIS                       |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ILEAL PERFORATION                               |                 |                |                |



|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ILEAL STENOSIS                                  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ILEUS   |                 |                |                |
| subjects affected / exposed                     | 2 / 745 (0.27%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| INTESTINAL ISCHAEMIA                            |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| INTESTINAL OBSTRUCTION                          |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 1 / 68 (1.47%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| INTESTINAL STENOSIS                             |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| LARGE INTESTINE PERFORATION                     |                 |                |                |
| subjects affected / exposed                     | 2 / 745 (0.27%) | 1 / 68 (1.47%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| NAUSEA  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| PANCREATITIS ACUTE                              |                 |                |                |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| SMALL INTESTINAL OBSTRUCTION                    |                 |                |                |
| subjects affected / exposed                     | 2 / 745 (0.27%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| SUBILEUS  |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| TERMINAL ILEITIS                                |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| VOMITING  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                 |                |                |
| BILE DUCT STONE                                 |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| CHOLANGITIS                                     |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| CHOLECYSTITIS ACUTE                             |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| HEPATIC FUNCTION ABNORMAL                       |                 |                |                |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| LIVER DISORDER                                  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                 |                |                |
| RASH  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Renal and urinary disorders                     |                 |                |                |
| CALCULUS URINARY                                |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 1 / 67 (1.49%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| HYDRONEPHROSIS                                  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| NEPHROLITHIASIS                                 |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| URETEROLITHIASIS                                |                 |                |                |
| subjects affected / exposed                     | 2 / 745 (0.27%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                 |                |                |
| ANKYLOSING SPONDYLITIS                          |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| ARTHRALGIA                                      |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| FIBROMYALGIA                                    |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| FISTULA   |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| SPONDYLITIS                                     |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| Infections and infestations                     |                 |                |                |
| ABDOMINAL WALL ABSCESS                          |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ABSCESS INTESTINAL                              |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| ANAL ABSCESS                                    |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| APPENDICITIS                                    |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| GASTROENTERITIS                                 |                 |                |                |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>GASTROENTERITIS NOROVIRUS</b>                |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>LEPTOSPIROSIS</b>                            |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>LOWER RESPIRATORY TRACT INFECTION</b>        |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>PERITONITIS</b>                              |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 1 / 68 (1.47%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>PNEUMONIA</b>                                |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>PULMONARY SEPSIS</b>                         |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>PYELONEPHRITIS</b>                           |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>TONSILLITIS</b>                              |                 |                |                |

|   |                 |                |                |
|---|-----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>URINARY TRACT INFECTION</b>                  |                 |                |                |
| subjects affected / exposed                     | 1 / 745 (0.13%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |
| <b>VULVAL CELLULITIS</b>                        |                 |                |                |
| subjects affected / exposed                     | 0 / 745 (0.00%) | 0 / 68 (0.00%) | 0 / 67 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0          | 0 / 0          |

| <b>Serious adverse events</b>                               | Period 2<br>Risankizumab<br>1200mg IV | Period 2<br>Risankizumab total | Period 2<br>Placebo/Risankizumab<br>1200mg IV |
|---|---------------------------------------|--------------------------------|---|
| Total subjects affected by serious adverse events           |                                       |                                |   |
| subjects affected / exposed                                 | 4 / 67 (5.97%)                        | 14 / 278 (5.04%)               | 4 / 76 (5.26%)                                |
| number of deaths (all causes)                               | 0                                     | 0                              | 0   |
| number of deaths resulting from adverse events              | 0                                     | 0                              | 0   |
| <b>Vascular disorders</b>                                   |                                       |                                |   |
| <b>DEEP VEIN THROMBOSIS</b>                                 |                                       |                                |   |
| subjects affected / exposed                                 | 0 / 67 (0.00%)                        | 0 / 278 (0.00%)                | 0 / 76 (0.00%)                                |
| occurrences causally related to treatment / all             | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| <b>HYPERTENSION</b>   |                                       |                                |   |
| subjects affected / exposed                                 | 0 / 67 (0.00%)                        | 0 / 278 (0.00%)                | 0 / 76 (0.00%)                                |
| occurrences causally related to treatment / all             | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| <b>Surgical and medical procedures</b>                      |                                       |                                |   |
| <b>ABORTION INDUCED</b>                                     |                                       |                                |   |
| subjects affected / exposed                                 | 0 / 67 (0.00%)                        | 0 / 278 (0.00%)                | 0 / 76 (0.00%)                                |
| occurrences causally related to treatment / all             | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| deaths causally related to treatment / all                  | 0 / 0                                 | 0 / 0                          | 0 / 0   |
| <b>General disorders and administration site conditions</b> |                                       |                                |   |
| <b>ASTHENIA</b>   |                                       |                                |   |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| SYSTEMIC INFLAMMATORY RESPONSE SYNDROME         |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Immune system disorders                         |                |                 |                |
| FOOD ALLERGY                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders |                |                 |                |
| ASTHMA  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| PULMONARY EMBOLISM                              |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Psychiatric disorders                           |                |                 |                |
| MENTAL DISORDER                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| OBSESSIVE-COMPULSIVE DISORDER                   |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Investigations                                  |                |                 |                |
| BODY TEMPERATURE INCREASED                      |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| HAEMOGLOBIN DECREASED                           |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| WEIGHT DECREASED                                |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications  |                |                 |                |
| FALL  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| FOREARM FRACTURE                                |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                |                 |                |
| VENTRICULAR TACHYCARDIA                         |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                |                 |                |
| DIZZINESS                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| SYNCOPE   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |



|   |                |                 |                |
|---|----------------|-----------------|----------------|
| Blood and lymphatic system disorders            |                |                 |                |
| ANAEMIA   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                |                 |                |
| RETINAL DISORDER                                |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 1 / 76 (1.32%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                |                 |                |
| ABDOMINAL HERNIA                                |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ABDOMINAL PAIN                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| COLITIS   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| CROHN'S DISEASE                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| DIARRHOEA                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| GASTROINTESTINAL HAEMORRHAGE                    |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| GASTROINTESTINAL INFLAMMATION                   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| GASTROINTESTINAL NECROSIS                       |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ILEAL PERFORATION                               |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ILEAL STENOSIS                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ILEUS   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| INTESTINAL ISCHAEMIA                            |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| INTESTINAL OBSTRUCTION                          |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 3 / 278 (1.08%) | 1 / 76 (1.32%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 3           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| INTESTINAL STENOSIS                             |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>LARGE INTESTINE PERFORATION</b>              |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>NAUSEA</b>                                   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>PANCREATITIS ACUTE</b>                       |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>SMALL INTESTINAL OBSTRUCTION</b>             |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>SUBILEUS</b>                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 1 / 76 (1.32%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>TERMINAL ILEITIS</b>                         |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>VOMITING</b>                                 |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>Hepatobiliary disorders</b>                  |                |                 |                |
| <b>BILE DUCT STONE</b>                          |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| CHOLANGITIS                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| CHOLECYSTITIS ACUTE                             |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| HEPATIC FUNCTION ABNORMAL                       |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| LIVER DISORDER                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                |                 |                |
| RASH  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Renal and urinary disorders                     |                |                 |                |
| CALCULUS URINARY                                |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| HYDRONEPHROSIS                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| NEPHROLITHIASIS                                 |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| URETEROLITHIASIS                                |                |                 |                |
| subjects affected / exposed                     | 1 / 67 (1.49%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                 |                |
| ANKYLOSING SPONDYLITIS                          |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ARTHRALGIA                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| FIBROMYALGIA                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| FISTULA   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| SPONDYLITIS                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                |                 |                |
| ABDOMINAL WALL ABSCESS                          |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| ABSCCESS INTESTINAL                             |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| ANAL ABSCESS                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| APPENDICITIS                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| GASTROENTERITIS                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| GASTROENTERITIS NOROVIRUS                       |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 1 / 76 (1.32%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1           | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| LEPTOSPIROSIS                                   |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| LOWER RESPIRATORY TRACT INFECTION               |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| PERITONITIS                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 1 / 278 (0.36%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| PNEUMONIA                                       |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>PULMONARY SEPSIS</b>                         |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>PYELONEPHRITIS</b>                           |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>TONSILLITIS</b>                              |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>URINARY TRACT INFECTION</b>                  |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| <b>VULVAL CELLULITIS</b>                        |                |                 |                |
| subjects affected / exposed                     | 0 / 67 (0.00%) | 0 / 278 (0.00%) | 0 / 76 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Period 1<br>Risankizumab<br>1200mg IV | Period 1 Placebo IV | Period 1<br>Risankizumab<br>600mg IV |
|---|---------------------------------------|---------------------|--------------------------------------|
| Total subjects affected by non-serious adverse events |                                       |                     |                                      |
| subjects affected / exposed                           | 58 / 372 (15.59%)                     | 35 / 186 (18.82%)   | 67 / 373 (17.96%)                    |
| <b>Nervous system disorders</b>                       |                                       |                     |                                      |
| <b>HEADACHE</b>                                       |                                       |                     |                                      |
| subjects affected / exposed                           | 20 / 372 (5.38%)                      | 8 / 186 (4.30%)     | 24 / 373 (6.43%)                     |
| occurrences (all)                                     | 27                                    | 8                   | 25                                   |

|   |                        |                        |                        |
|---|------------------------|------------------------|------------------------|
| Blood and lymphatic system disorders<br>ANAEMIA<br>subjects affected / exposed<br>occurrences (all) | 9 / 372 (2.42%)<br>9   | 5 / 186 (2.69%)<br>5   | 11 / 373 (2.95%)<br>11 |
| Gastrointestinal disorders<br>CROHN'S DISEASE<br>subjects affected / exposed<br>occurrences (all)   | 4 / 372 (1.08%)<br>4   | 10 / 186 (5.38%)<br>10 | 5 / 373 (1.34%)<br>5   |
| NAUSEA<br>subjects affected / exposed<br>occurrences (all)  | 13 / 372 (3.49%)<br>13 | 10 / 186 (5.38%)<br>10 | 16 / 373 (4.29%)<br>17 |
| Infections and infestations<br>NASOPHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)  | 22 / 372 (5.91%)<br>24 | 5 / 186 (2.69%)<br>5   | 22 / 373 (5.90%)<br>24 |

| <b>Non-serious adverse events</b>   | Period 1<br>Risankizumab total | Period 2<br>Risankizumab<br>360mg SC | Period 2<br>Risankizumab<br>180mg SC |
|---|--------------------------------|--------------------------------------|--------------------------------------|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed                | 125 / 745 (16.78%)             | 7 / 68 (10.29%)                      | 4 / 67 (5.97%)                       |
| Nervous system disorders<br>HEADACHE<br>subjects affected / exposed<br>occurrences (all)            | 44 / 745 (5.91%)<br>52         | 3 / 68 (4.41%)<br>3                  | 1 / 67 (1.49%)<br>2                  |
| Blood and lymphatic system disorders<br>ANAEMIA<br>subjects affected / exposed<br>occurrences (all) | 20 / 745 (2.68%)<br>20         | 2 / 68 (2.94%)<br>2                  | 0 / 67 (0.00%)<br>0                  |
| Gastrointestinal disorders<br>CROHN'S DISEASE<br>subjects affected / exposed<br>occurrences (all)   | 9 / 745 (1.21%)<br>9           | 1 / 68 (1.47%)<br>1                  | 2 / 67 (2.99%)<br>2                  |
| NAUSEA<br>subjects affected / exposed<br>occurrences (all)  | 29 / 745 (3.89%)<br>30         | 0 / 68 (0.00%)<br>0                  | 1 / 67 (1.49%)<br>1                  |
| Infections and infestations<br>NASOPHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)  | 44 / 745 (5.91%)<br>48         | 1 / 68 (1.47%)<br>1                  | 1 / 67 (1.49%)<br>1                  |



| <b>Non-serious adverse events</b>   | Period 2<br>Risankizumab<br>1200mg IV          | Period 2<br>Risankizumab total                   | Period 2<br>Placebo/Risankizumab<br>1200mg IV  |
|---|--|--|--|
| Total subjects affected by non-serious adverse events<br>subjects affected / exposed  | 4 / 67 (5.97%)                                 | 27 / 278 (9.71%)                                 | 12 / 76 (15.79%)                               |
| Nervous system disorders<br>HEADACHE<br>subjects affected / exposed<br>occurrences (all)  | 2 / 67 (2.99%)<br>3                            | 11 / 278 (3.96%)<br>13                           | 5 / 76 (6.58%)<br>5                            |
| Blood and lymphatic system disorders<br>ANAEMIA<br>subjects affected / exposed<br>occurrences (all)   | 1 / 67 (1.49%)<br>1                            | 7 / 278 (2.52%)<br>7                             | 4 / 76 (5.26%)<br>4                            |
| Gastrointestinal disorders<br>CROHN'S DISEASE<br>subjects affected / exposed<br>occurrences (all)<br><br>NAUSEA<br>subjects affected / exposed<br>occurrences (all) | 0 / 67 (0.00%)<br>0<br><br>0 / 67 (0.00%)<br>0 | 3 / 278 (1.08%)<br>3<br><br>4 / 278 (1.44%)<br>4 | 0 / 76 (0.00%)<br>0<br><br>3 / 76 (3.95%)<br>3 |
| Infections and infestations<br>NASOPHARYNGITIS<br>subjects affected / exposed<br>occurrences (all)  | 1 / 67 (1.49%)<br>1                            | 5 / 278 (1.80%)<br>5                             | 2 / 76 (2.63%)<br>2                            |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment   |
|-------------------|---|
| 05 July 2017      | <p>Major changes included:</p> <p>Added CDAI criteria to the inclusion criteria.</p> <p>Updated instructions on which hematocrit (Hct) value to use in calculating the CDAI for inclusion.</p> <p>Added "psychological or psychiatric cause" to Exclusion Criterion 29.</p> <p>Updated information on discontinuation of individual subjects for subjects who were not responders at Week 12.</p> <p>Updated contraception recommendations and criteria.</p> <p>Clarification of the blind-breaking process.</p> <p>Updated latent tuberculosis (TB) requirements.</p> <p>Updated pregnancy reporting timing.</p> <p>Added assent information for subjects less than 18 years old.</p>  |
| 29 September 2017 | <p>Major changes included:</p> <p>Added an anaphylaxis adjudication committee.</p> <p>Revised to allow for local regulations for the difference in minimum age for adults.</p> <p>Updated of Inclusion Criterion 6 for immunomodulators (IMM) use.</p> <p>Updated of Exclusion Criterion 18 for CD related complications.</p> <p>Updated of prohibited medications.</p> <p>Added international normalized ratio (INR) and anaphylaxis testing.</p> <p>Added details for additional hepatitis testing and anaphylaxis testing.</p> <p>Added endoscopic remission to ranked secondary endpoints and Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) to non ranked secondary endpoints.</p> <p>Added clinical and endoscopic remission over time as endpoints.</p> <p>Updated criteria for discontinuation of individual subjects.</p> <p>Revised to align with Common Toxicity Criteria for Adverse Events (CTCAE) grading criteria for adverse events (AEs).</p> <p>Revised to allow for additional types of anaphylactic reactions and to provide Investigators with guidance on reporting of events.</p> <p>Updated for alignment with template requirements and for consistency across the risankizumab programs.</p> <p>Clarifications of sample size calculation.</p> <p>Updated to reflect the most recent subject diary entries and addition of patient-reported outcome (PRO) for collection.</p> <p>Updated in the schedule of activities to reflect changes made in the body of the protocol.</p> <p>Addition of information on the sample collection schedule.</p> <p>Revised to align with regulatory agency feedback.</p> |

|                  |  |
|------------------|--|
| 09 July 2018     | <p>Major changes included:</p> <p>Extension of the AE collection period duration, final follow-up call, and period for prohibition of vaccines.</p> <p>Modified benefits and risks to align with the IB.</p> <p>Added blood collection for tryptase following a suspected drug administration hypersensitivity reaction.</p> <p>Added "worsening" CD to common AEs associated with underlying disease.</p> <p>Added "intramuscular" as possible route of administration for prohibited anti-infectives.</p> <p>Exclusion of subjects who receive exclusive enteral nutrition to treat CD.</p> <p>Clarification and explanation of inclusion requirements for oral locally acting steroids, IV or oral systemic steroids.</p> <p>Added height measurement for pediatric subjects.</p> <p>Prohibition of local, routine testing for fecal calprotectin and high-sensitivity C-reactive protein.</p> <p>Modified contraception language.</p> <p>Removed stool sample collection for fecal-calprotectin (FCP) at screening.</p> <p>Clarified repeat screening tests and the qualifications for a screening period extension.</p>   |
| 22 February 2019 | <p>Major changes included:</p> <p>Documentation of the DMC opinion to continue the trial and enroll 16-17 year olds.</p> <p>Added language to allow single repeat testing of transient exclusionary laboratory values during the screening period.</p> <p>Clarified the types of prohibited corticosteroids.</p> <p>Modified permit enrollment of not more than 20% subjects with prior exposure, including intolerance or inadequate response, to ustekinumab</p> <p>Specification that enrollment of subjects with Baseline SES-CD of <math>\geq 3</math> to <math>&lt; 6</math> for ileocolonic or colonic disease or Baseline SES-CD of 3 for isolated ileal disease would be no more than 10% of the total population.</p> <p>Added stratification factor of Baseline SES-CD.</p> <p>Updated definitions of endoscopic remission and endoscopic response.</p> <p>Revised to allow a commercially available assay to determine approved biologic washout.</p> <p>Clarified that TB prophylaxis is permissible.</p> <p>Revised the order and addition of ranked secondary endpoints, update of ranked secondary endpoints to non ranked secondary endpoints, and addition of non-ranked secondary endpoint.</p> <p>Updated statistical assumptions for sample size determination.</p> <p>Added details of multiplicity adjustment and subgroup analysis for Bio-IR and non Bio-IR population.</p> <p>Updated of the missing imputation methodology to remove last observation carried forward (LOCF).</p> |
| 19 December 2019 | <p>Major changes included:</p> <p>Specified total N of 855 for the primary intent-to-treat (ITT) population used for efficacy analysis, that the number of subjects with lower SES-CD will be no more than 85, and that data collected from subjects with the lower SES-CD will be analyzed as an exploratory efficacy analysis.</p> <p>Specified that Hct from the preceding visit may be used to calculate the CDAI if there are technical issues.</p> <p>Revised the definition of endoscopic remission.</p> <p>Revised the term "endoscopic healing" to "ulcer-free endoscopy".</p> <p>Updated of secondary endpoint ranking and combining and adding new ranked secondary endpoints.</p> <p>Clarified timing of DBL Removed the missing imputation method OC from the sensitivity analysis of the continuous efficacy variables.</p> <p>Added missing data handling methods.</p> <p>Clarified the way continuous laboratory and vital signs would be summarized.</p> <p>Removed Fisher's exact test for risankizumab treatment group differences versus placebo for AEs.</p>  |

|              |  |
|--------------|--|
| 28 July 2020 | Major changes included:<br>Revised language throughout due to the Coronavirus disease – 2019 (COVID-19) pandemic, including benefit and risk, criteria to exclude subjects with active COVID-19, addition of COVID-19 AE data collection process, modification of study visits/protocol-specified procedures impacted by changes in local regulations, protocol deviations, missing data, data monitoring, and COVID-19 testing. Added language regarding site responsibility. Clarified HIV results language. |
|--------------|--|

Notes:

---

## **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported